H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:VRAX), a U.K.-based company focused on detecting ...

T cells are white blood cells that are important for adaptive immunity. They have unique cell surface receptors that are generated by randomly assorting genes. These receptors allow T cells to ...

2024: Leica Microsystems introduced TauSTED Xtend, a breakthrough in STED microscopy. This new approach allows for extended ...

Virax Biolabs begins enrolling patients in clinical study assessing T cell dysfunction in post-acute infection syndromes: London Wednesday, March 19, 2025, 16:00 Hrs [IST] Virax B ...

More about Virax Biolabs Group Ltd. Class A Virax Biolabs ... The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, particularly effective ...

Virax Biolabs (VRAX) has started enrolling patients into its United Kingdom based, multi-center clinical study. Conducted in collaboration with ...

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today ...

Virax Biolabs Group Limited is currently developing T cell-based test technologies with the intention of providing an immunology profiling platform. T cell testing can be particularly effective in ...

LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis, has ...

Bris­tol My­ers Squibb will ac­quire its CAR-T cell ther­a­py col­lab­o­ra­tor 2sev­en­ty bio for $286 mil­lion in cash, the com­pa­nies said late Mon­day evening.